Xanthine oxidoreductase expression is diminished in breast cancer as a response to uric acid mediated chelation of redox active iron.

ABSTRACT: Breast cancer patients with diminished xanthine oxidoreductase (XOR) expression have a greater risk for metastases and diminished survival; however, the mechanisms underpinning this phenomenon are unknown. Under normal growth conditions, neither triple negative MDA-MB-231 nor ER-positive MCF-7 cells demonstrated detectable expression of XOR mRNA, protein and enzymatic activity, which was confirmed using archived in silico data. Enforced expression of XOR did not yield viable cells with significant increases in XOR protein and activity. In addition, exposing breast cancer cells to clinically relevant concentrations of UA diminished growth, migratory capacity, and clonogenic cell survival. Parallel experiments with iron chelators (e.g., DTPA or DFO) produced similar effects, suggesting a pot

SUBMITTER: Chapa MG 

PROVIDER: S-EPMC12750285 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature